Outcomes in ICH Patients Should be stratified by Age with Attention to Race and ICH Score (P6.012)

Objective: To compare the distributions of Charlson Comorbidity Index (CCI) Scores between among blacks and whites with ICH, stratifying by age, and examined the impact on outcomes. Background: Assessing disparities in outcomes among ICH patients is challenging given (1) the higher prevalence of some vascular risk factors and earlier age among blacks, (2) the strong association between ICH score and outcome, and (3) the uncertain effect of comorbidities on outcome. Methods: Retrospective review of primary ICH patients with ICH scores 0-2 presenting to a tertiary academic center (2008-2013), excluding patients transitioned to palliative care. Patients were grouped according to age =65. Blacks and whites were compared within each age strata with respect to CCI and poor short-term functional outcome (defined as discharge modified Rankin Scale 4-6). Results: A total of 238 patients met inclusion criteria (mean age 63, 41[percnt] black, 43[percnt] female). Blacks were younger (57 vs 70 years; p<0.0001). Whites had higher median CCI scores (5 vs 3; p<0.0001). Overall, blacks were less likely to have a poor outcome (OR 0.65, 95[percnt]CI 0.41-1.03); this effect remained after adjusting for CCI score (OR 0.69, 95[percnt]CI 0.43-1.09). The median CCI scores for blacks and whites were identical (1 at age <45, 3 at age 45-64, and 5 at age =65). Blacks were more likely to have a poor outcome at age<45, while whites were more likely to have a poor outcome at ages 45 and older. Discussion: We observed identical median CCI scores for whites and blacks within each age group. Although whites with ICH appeared to have more comorbidities, this was explained by their older age. After taking age into account, blacks more frequently had poor short-term functional outcome in the younger group, whereas whites more frequently had poor short-term functional outcome in middle and older age groups. Disclosure: Dr. Boehme has nothing to disclose. Dr. Albright has nothing to disclose. Dr. Sisson has nothing to disclose. Dr. Hays Shapshak has nothing to disclose. Dr. Kumar has nothing to disclose. Dr. Elkind has received personal compensation for activities with BMS-Pfizer Partnership, Janssen Pharmaceuticals, Daiichi-Sankyo, Boehringer-Ingelheim Biogen IDEC, Biotelemetry and Organon/Merk as a consultant. Dr. Elkind has received personal compensati Dr. Harrigan has nothing to disclose.